Surrogate viruses for use in disinfectant efficacy tests to justify claims against COVID-19

The following surrogate viruses can be used:

• Human coronavirus 229E
• Murine hepatitis virus.

As outlined above, if Human coronavirus 229E or Murine hepatitis virus cannot be used, consideration will be given on a case-by-case basis to the use of other human or animal coronaviruses, with an appropriate justification. Viruses that have been suggested include Bovine coronavirus and Feline coronavirus.

No. Viruses other than those that are coronaviruses cannot be used to justify label claims against COVID-19 for hard surface disinfectants and disinfectants that are medical devices.

For hard surface disinfectants, details of the testing required are found in the TGA instructions for disinfectant testing under Part 2, Division 2: Specific tests for hospital grade disinfectants and household/commercial grade disinfectants - Virucidal testing.

For disinfectants that are medical devices, details can be found in the Guidelines for the evaluation of sterilants and disinfectants in Section 6.4.5 Virucidal tests.

All tests should be carried out by a GMP licensed laboratory or laboratory accredited to ISO/IEC 17025 or equivalent, such as (but not limited to) NATA, TGA, US FDA, PIC/S, US EPA, or UKAS. If requested, statements assuring adherence to Good Laboratory Practice (GLP) should be provided.

Hard surface disinfectants and disinfectants that are medical devices are regulated by the Medical Devices Authorisation Branch (MDAB) of the TGA. Hard surface disinfectants are regulated as 'Other therapeutic goods', and disinfectants that are intended to be used on medical devices are regulated as medical devices.

Hard surface disinfectants with a label claim against COVID-19 (or a claim against viruses, spores, tuberculosis, mycobacteria or fungi) must be listed on the ARTG; therefore, an application for listing must be made. Refer to Guidance on the regulation of listed disinfectants in Australia for more information.

For disinfectants that are medical devices, an application for inclusion on the ARTG must be made.

On 24 April 2020, the TGA issued legal permission for specified disinfectants to include claims of efficacy against SARS-CoV-2, which had previously been a prohibited representation. The Permission can be found on the TGA website.

You should ensure that you have all the data that you need to support your proposed COVID-19 claim or any other specific claims that you wish to make. Please note that the TGA does not provide a pre-evaluation service.

If you have any questions about applications for disinfectants, contact the Medical Device Information Service at devices@tga.gov.au or 1800 141 144.

For hard surface disinfectants and disinfectants that are medical devices, a Device Change Request application must be made.

On 24 April 2020, the TGA issued legal permission for specified disinfectants to include claims of efficacy against SARS-CoV-2, which had previously been a prohibited representation. The Permission can be found on the TGA website.

You should ensure that you have all the data that you need to support your proposed COVID-19 claim or any other specific claims that you want to make. Please note that the TGA does not provide a pre-evaluation service.

If you have any questions about applications for disinfectants, contact the Medical Device Information Service at devices@tga.gov.au or 1800 141 144.